AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Nicole DeFeudis

Editor

Despite a bumpy takeoff, AbbVie has some big plans for Vraylar, the blockbuster schizophrenia and bipolar drug it snapped up from Allergan a couple of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Ab­b­Vie sees a megablock­buster in Vray­lar. Could a new de­pres­sion in­di­ca­tion push peak sales past $4B?

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?